Related by context. All words. (Click for frequent words.) 74 oral prodrug 74 MKC# MKC# PP 74 Archexin 73 Elagolix 73 investigational humanized monoclonal antibody 73 MKC# MT 73 IMA# 73 Phase III Clinical Trial 73 Romidepsin 73 Tezampanel 72 Phase IIb Trial 72 Glufosfamide 72 Dapagliflozin 72 Pertuzumab 72 leading oral taxane 72 multi kinase inhibitor 72 Bavituximab 72 investigational pan BCR 72 Hsp# Inhibitor 72 pan HDAC inhibitor 72 Phase 2b Clinical Trial 72 Aflibercept 72 Cloretazine ® 72 PDE4 inhibitor 72 Metastatic Melanoma 72 immunotherapeutic agent 71 mertansine 71 Meets Primary Endpoint 71 Pivotal Phase III 71 Ridaforolimus 71 Ceflatonin R 71 Alocrest 71 Phase III Pivotal 71 Carfilzomib 71 Phase Ib study 71 selective orally bioavailable 71 Pivotal Phase 71 Omacetaxine 71 Factor VIIa 71 Randomized Phase 71 Sym# 71 PI3K/Akt pathway inhibitor 71 Initiated Phase 70 HuMax EGFr 70 Personalized Immunotherapy 70 liposomal formulation 70 CYT# potent vascular disrupting 70 TRO# 70 Talabostat 70 Epratuzumab 70 orally administered inhibitor 70 Mipomersen 70 Deforolimus 70 Phase #b/#a clinical 70 Rigel R# 70 Elesclomol 70 Blinatumomab 70 candidate deforolimus 70 FOLOTYN ® 70 Dalbavancin 70 Phase 2a Clinical Trial 70 acyclovir Lauriad R 70 trastuzumab DM1 T DM1 70 Completes Patient Enrollment 70 telomerase therapeutic 70 PEGylated Fab fragment 70 Clinical Trial Results 70 TKB# 70 solithromycin 70 Cyclooxygenase Inhibiting Nitric Oxide 70 pharmacokinetic PK study 70 Combination REOLYSIN R 70 phase IIb clinical 70 including eniluracil ADH 70 Tyrosine Kinase Inhibitor 70 targeted radiotherapeutic 70 Phase III Clinical Trials 70 AKT inhibitor 70 Squalamine 70 Initiates Phase II 70 PDX pralatrexate 70 Quinamed 70 non nucleoside inhibitor 70 YONDELIS 70 motexafin gadolinium Injection 69 Aliskiren 69 Aganocide 69 antibody MAb 69 Panzem R NCD 69 Dasatinib 69 agonistic human 69 Daclizumab 69 oral ghrelin agonist 69 Traficet EN 69 ganetespib 69 JAK Inhibitor 69 radiation sensitizer 69 Initiates Enrollment 69 Vicriviroc 69 sodium glucose cotransporter 69 Novel Oral 69 Presents Preclinical Data 69 hypoxia activated prodrug 69 Maribavir 69 MAGE A3 ASCI 69 IAP inhibitors 69 DermaVir Patch 69 Files IND 69 ZEVALIN ® 69 Aplidin R 69 histone deacetylase HDAC inhibitor 69 Interferon Gamma 69 Safinamide 69 Initiate Clinical Trial 69 receptor tyrosine kinase inhibitor 69 Delafloxacin 69 KRN# 69 GW# [003] 69 Pazopanib 69 Immunotherapeutic 69 GVAX ® 69 Radezolid 69 CYC# 69 Voreloxin 69 AEG# 69 Oral NKTR 69 intranasal formulation 69 Golimumab 69 huC# DM4 69 Solazed TM 69 candidate CRLX# 69 Pafuramidine 69 docetaxel Taxotere R 69 docetaxel Taxotere ® 69 Nanobody 69 Belimumab 69 Zalypsis 69 PNP inhibitor 69 IMiDs R 69 AAG geldanamycin analog 69 5 HT3 antagonist 69 oral anticancer 68 anticancer compound 68 sunitinib Sutent ® 68 investigational monoclonal antibody 68 HCV protease inhibitor 68 Cetrorelix 68 ocular formulation 68 Preclinical Data 68 Bortezomib 68 SPL# Gel vaginal microbicide 68 forodesine 68 imatinib Gleevec ® 68 tiapamil 68 Intravenous Human 68 Besivance 68 Transdermal Patch 68 oral proteasome inhibitor 68 fosbretabulin 68 Silodosin 68 PSMA ADC 68 Xanafide 68 Sapacitabine 68 Bazedoxifene 68 Novolimus 68 LymphoStat B TM 68 HQK 68 Antigenics QS 68 targeted antifolate 68 BAL# [002] 68 vinca alkaloid 68 Initiate Phase 68 pralatrexate injection folate analogue 68 Nitazoxanide 68 Albuferon TM 68 Pivotal Trial 68 Anti Tumor 68 First Patient Dosed 68 HDAC Inhibitor 68 multitargeted 68 Ostabolin C 68 BAY #-# 68 Bafetinib 68 IMiDs ® 68 Degarelix 68 Irinotecan 68 OMP #M# 68 Levoleucovorin 68 selective androgen receptor modulator 68 oral Janus kinase 68 polymerase inhibitor 68 Vandetanib 68 allosteric modulator NAM 68 proteasome inhibitor 68 PEG SN# 68 INCB# [001] 68 Humanized Anti 68 humanized anti 68 candidate XP# 68 Vicinium TM 68 Phase III Trial 68 Dose Escalation 68 R#/MEM # 68 Anidulafungin 68 Successfully Completes Phase 68 Phase 2b Study 68 assessing T DM1 68 IMC #B 68 Initiates Phase III 68 Tofacitinib 68 investigational antiplatelet agent 68 Phase 1a clinical 68 BiTE R 68 Allovectin 7 68 Naproxcinod 68 vinorelbine tartrate 68 orally bioavailable 68 Telatinib 68 delta opioid receptor 68 Spiegelmer ® 68 BRIM2 68 Perifosine 68 Diabetic Macular Edema DME 68 novel peptide 68 ZK EPO 68 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 68 Methylnaltrexone 68 Denufosol 68 delafloxacin 68 BAL# [001] 68 dasatinib Sprycel ® 68 Aptamer 68 ENMD # 68 Initiates Clinical 68 ELACYT 68 Metastatic Colorectal Cancer 68 registrational trial 68 LymphoStat B belimumab 68 TLK# 68 Bosutinib 68 vascular disrupting agent 68 Pralatrexate 68 HIV integrase inhibitors 68 Antitumor Activity 67 Ozarelix 67 product candidate Lpathomab 67 OncoVex 67 Phase Ib II 67 therapeutic monoclonal antibody 67 vidofludimus 67 MKC# 67 NPC 1C 67 Hedgehog Pathway Inhibitor 67 Ceftaroline 67 nucleoside analog 67 Cleviprex TM clevidipine 67 selective immunoproteasome inhibitor 67 Oritavancin 67 Novel Antibiotic 67 sodium thiosulfate STS 67 Drug Candidate 67 Saxagliptin 67 Elvitegravir 67 CRLX# 67 Azedra 67 Laquinimod 67 Pemetrexed 67 signal transduction inhibitor 67 Hormone Refractory Prostate Cancer 67 CCX# 67 personalized cellular immunotherapy 67 vemurafenib 67 Exherin TM 67 Tarvacin TM 67 Phase 2b Trial 67 DIRECT Trial 67 ADP receptor antagonist 67 pertuzumab 67 metaglidasen 67 Xcytrin R 67 oncolytic virus therapies 67 EXPAREL TM 67 ATL/TV# 67 Kinase Inhibitor 67 JAK1 67 Angiocept 67 Valopicitabine 67 mGluR5 negative 67 Phase IIb Clinical Trial 67 Investigational Oral 67 AFREZZA TM 67 PrevOnco 67 cathepsin K inhibitor 67 somatostatin analogue 67 Cotara ® 67 treat refractory angina 67 Preclinical Study 67 Neulasta ® 67 Replacement Therapy 67 peripherally acting 67 novel VDA molecule 67 Pivotal Phase II 67 SPRYCEL ® 67 IAP inhibitor 67 XL# XL# 67 APEX PD 67 VEGFR2 inhibitor 67 non peptidic protease 67 ZACTIMA 67 XmAb 67 initiated Phase Ib 67 Elotuzumab 67 dasatinib Sprycel 67 ALN PCS 67 Liposomal 67 rxRNA 67 CR# vcMMAE 67 selective antagonist 67 selective kinase inhibitor 67 Phase 1b clinical trials 67 Aplidin 67 CBLC# 67 ABL inhibitor 67 Patient Enrollment 67 RNAi Therapeutic 67 Qutenza TM 67 Study Evaluating 67 Oral Insulin 67 chimeric monoclonal antibody 67 NVA# 67 alvespimycin 67 RhuDex 67 TAFA# 67 Aurora Kinase 67 Zolinza 67 ALN TTR 67 candidates Azedra 67 Melphalan 67 Temsirolimus 67 Ambrisentan 67 Complicated Skin 67 Dose Ranging Study 67 monoclonal antibody conjugated 67 Alfacell proprietary ribonuclease 67 Myocet 67 recurrent metastatic ovarian cancer 67 novel histone deacetylase 67 Akt inhibitor 67 Luteinizing Hormone Releasing Hormone 67 MEK inhibitor 67 candidate AQ4N 67 Pivotal Study 67 Therapeutic Vaccine 67 CEQ# 67 generation antisense 67 Commences Phase 67 Unit Dose Budesonide 67 Achieves Primary Endpoint 67 Panzem R 67 Nexavar ® 67 ALN HPN 67 Phase #b/#a trial 67 Virulizin ® 67 Alferon N 67 Lodotra TM 67 GRNVAC1 67 PSN# [002] 67 Adjuvant Treatment 67 Ofatumumab 67 topical gel formulation 67 RGB # 67 Investigational Compound 67 ONCONASE R 67 Phase III Trials 67 sorafenib tablets 66 unique alkylating agent 66 Trastuzumab 66 JAK inhibitor 66 selective estrogen receptor modulator 66 Homspera TM 66 Enzastaurin 66 generation Hsp# inhibitor 66 Lubiprostone 66 IL# PE#QQR 66 therapeutic monoclonal antibodies 66 topically applied SEPA 66 Indaflex TM 66 Treatment Naïve 66 randomized controlled Phase 66 LEVADEX TM 66 RhuDex ® 66 Linaclotide 66 PRTX 66 Monoclonal Antibody 66 torezolid 66 INS# [001] 66 Bioral ® 66 DUROS 66 Kahalalide F 66 humanized monoclonal 66 Ophena TM 66 CCR9 antagonist 66 Romiplostim 66 Onco TCS 66 ARRY # 66 angiogenesis inhibitor 66 oral ridaforolimus 66 Eculizumab 66 IMiD 66 Advaxis Phase 66 MyVax R 66 compound perifosine 66 Epidermal Growth Factor Receptor 66 Annamycin 66 taxane derivative 66 cilengitide 66 radezolid 66 CCR5 antagonist 66 Civacir 66 evaluating T DM1 66 Tyrima 66 Completes Enrollment 66 Patients Treated With 66 molecular imaging radiopharmaceutical 66 Curaxin CBLC# 66 Onconase 66 Advanced Renal Cell 66 Pruvel TM 66 renin inhibitor 66 II Clinical Trial 66 oral taxane 66 FUSILEV ® 66 ALN TTR# 66 GSK '# 66 DXL# 66 OMNARIS HFA 66 Thiarabine 66 Microplasmin 66 PLK1 SNALP 66 dependent kinase inhibitor 66 CD3 monoclonal antibody 66 protein kinase inhibitor 66 MEK Inhibitor 66 Cannabinor 66 Ceflatonin 66 Trial Evaluating 66 Inhalation Solution 66 Phase Ib clinical 66 tezampanel 66 Pathway Inhibitor 66 Tarceva TM 66 HuMax TAC 66 MT#/MEDI-# 66 TRX1 66 Receives Orphan Drug Designation 66 trial evaluating PRX# 66 Vidofludimus 66 Advanced Melanoma 66 evaluating tivozanib 66 HDL Mimetic Peptide 66 product platforms AZX# 66 Curaxin 66 Protease Inhibitor 66 Phase 2a Trial 66 HSP# inhibitor 66 HCV polymerase inhibitors 66 NS#/#A protease 66 Pharmacokinetic Study 66 ZD# [001] 66 Nilotinib 66 Oral Fingolimod 66 Bevacizumab 66 Hepatocellular Carcinoma 66 Zingo TM 66 cancer immunotherapies 66 erlotinib Tarceva ® 66 BENLYSTA ® 66 thalidomide Thalomid 66 Demonstrates Efficacy 66 apoptosis inducer 66 ospemifene 66 Alinia 66 LibiGel ® 66 JAK2 Inhibitor 66 PRT# 66 Cethromycin 66 IRX 2 66 Pimavanserin 66 Radiation Therapy SIRT 66 Anti VEGF 66 Alexza Staccato 66 Demonstrates Potent 66 Zorbtive TM 66 Aganocide ® 66 thiazolides 66 Locked Nucleic Acid LNA 66 OvaRex R 66 anticoagulant reversing agent 66 Vidaza R 66 oral nucleoside analogue 66 RAV# 66 3 registrational trial 66 oral dual endothelin 66 generation purine nucleoside 66 XYOTAX TM 66 Amrubicin 66 Phase IIb clinical trials 66 Thiovir 66 vascular disrupting agents 66 Ocrelizumab 66 intravesical infusion therapy 66 PANVAC VF 66 Darinaparsin 66 long acting muscarinic 66 Initiates Phase 66 targeting CD# 66 PKC# 66 HepeX B TM 66 Prolongs Survival 66 small molecule thrombopoietin 66 Phase 1b Clinical Trial 66 oral renin inhibitor 66 class anticancer quinolone 66 Clinical Trial Evaluating 66 2 methoxyestradiol 66 IMPDH inhibitor 66 Interferon beta 1a 66 budesonide foam 66 highly selective inhibitor 66 SinuNase ™ 66 Fast Track Status 66 delivery polymer matrix 66 rNAPc2 66 R roscovitine 66 DDP# 66 Antiangiogenic 66 Aptivus ® 65 virosome 65 LHRH antagonist 65 Bucindolol 65 NEUGENE 65 RECOTHROM R 65 Rasagiline 65 maturation inhibitor 65 Bicifadine 65 formerly LymphoStat B 65 sorafenib Nexavar 65 enhance ApoA 65 EOquin TM 65 SAR# [004] 65 JZP 65 novel oral anticoagulant 65 KNS # 65 oxybutynin gel 65 anti angiogenic agent 65 Ostabolin C TM 65 IND Filing 65 5 fluorouracil leucovorin 65 PEGylated 65 Tanespimycin 65 IMC A# 65 Muraglitazar 65 Panzem 65 rasagiline tablets 65 Nanobody ® 65 5 HT6 receptor 65 LE SN# 65 anti amnesic 65 SAR# [002] 65 XL# anticancer compounds 65 alemtuzumab Campath 65 lexidronam injection 65 rilonacept 65 Anti Tumor Activity 65 Novel Inhibitor 65 Oral Anticoagulant 65 developing Bicifadine serotonin 65 Locteron ® 65 Ustekinumab 65 CTAP# Capsules 65 novel topoisomerase 65 GV# [001] 65 peptidic compound 65 Begins Dosing 65 sapacitabine CYC# 65 BZL# 65 Iluvien ® 65 REG1 Anticoagulation System 65 Chemophase 65 Aurexis 65 CoFactor 65 SCIB1 65 PROSTVAC TM 65 tubulin inhibitor 65 Initiate Phase III 65 SUPPRELIN R LA 65 FTY# fingolimod 65 PEGylated anti 65 OXi# 65 velafermin 65 Iloperidone 65 Lenocta TM 65 VersaFilm 65 Aryplase 65 HGS ETR1 mapatumumab 65 PREOS R 65 TMC# [002] 65 orally inhaled migraine 65 accumulate preferentially 65 kidney urologic 65 Randomized Double blind 65 Bioral R 65 acetonide FA 65 SinuNase TM 65 peptibody 65 Locked Nucleic Acid 65 R bortezomib 65 M# rationally 65 Pharmacokinetics PK 65 XP# XP# 65 CD# monoclonal antibody 65 ELND-#/AZD-# 65 #I TM# 65 TACI Ig 65 Piperacillin 65 Serdaxin ® 65 Geron telomerase inhibitor 65 ® bortezomib 65 proteasome inhibitors 65 TG# [003] 65 TLR9 agonist 65 Sphingomab 65 Febuxostat 65 Kinase Inhibitors 65 AP# [003] 65 HCD# [002] 65 inhaled formulation 65 Teva Provides Update 65 Epeius Biotechnologies Corporation 65 acyclovir Lauriad ® 65 hormone LHRH antagonist 65 PHX# 65 octreotide acetate 65 mapatumumab 65 HGS ETR1 65 albiglutide 65 EndoTAG 65 armodafinil Tablets C 65 Lenocta 65 Aztreonam lysine 65 HCV Protease Inhibitor 65 Augment TM 65 Oral Mucositis 65 phase IIb trial 65 protein tyrosine phosphatase 1B 65 Alfimeprase 65 Diabetic Nephropathy 65 OHR/AVR# 65 Files Investigational 65 NU# direct 65 OvaRex ® MAb 65 Present Preclinical Data 65 Exherin 65 Symadex 65 Relapsed Multiple Myeloma 65 Prostate Cancer Vaccine 65 Wound Dressing 65 Cloretazine 65 Guanilib 65 Investigational Drug 65 Bicalutamide 65 Brentuximab Vedotin SGN 65 HCV NS5B polymerase 65 Dyloject TM 65 PEGylated interferon 65 HGS# 65 phase III isavuconazole 65 LEVADEX ™ 65 dextofisopam 65 orally dosed 65 Patient Enrolment 65 BiovaxID TM 65 Aztreonam 65 novel immunomodulatory 65 Phase IIa Clinical Trial 65 Adalimumab 65 evaluating satraplatin 65 SUTENT ® 65 Vaccine Adjuvant 65 Initiates Clinical Trial 65 Well Tolerated 65 torezolid phosphate 65 Interferon Beta 65 TRANSDUR Bupivacaine 65 Demonstrates Positive 65 systemic RNAi therapeutic 65 Resten NG 65 Trastuzumab DM1 65 ChronVac C R 65 HGS ETR2 65 LAB CGRP 65 TRANSDUR ® 65 romidepsin novel 65 relapsed multiple myeloma 65 elotuzumab 65 rALLy clinical trial 65 OncoVEX 65 generation antisense inhibitor 65 MEK inhibitors 65 Kamada AAT 65 Receives Approvable Letter 65 IMiDs ® compound 65 Xyfid TM 65 TNF Tumor Necrosis Factor 65 CD# CEA 65 autologous cellular immunotherapy 65 tesetaxel 65 Prostate AdenoCarcinoma Treatment 65 corticosteroid dexamethasone 65 ALGRX 65 Vitro Activity 65 tumor vascular disrupting 65 ixabepilone 65 Provectus Pharmaceuticals specializes 65 ANG# 65 topical antifungal 65 IgG1 monoclonal antibody 65 selective modulator 65 PGL# 65 CRMD# 65 Japanese Encephalitis vaccine 65 delivers fluocinolone acetonide FA 65 Ecallantide 65 Granted Orphan Drug 65 include Alferon N 65 subcutaneous formulation 65 Azixa 65 TRANSDUR ™ 65 Vaprisol 65 Bayer HealthCare Onyx Pharmaceuticals 65 Gleevec resistant 65 Proxinium TM 65 Fludara ® 65 Talactoferrin 65 HDL Selective Delipidation 65 Seliciclib 65 Enzyme Replacement Therapy 65 SUMAVEL 65 glucokinase activator 65 TBC# 65 DermaVir 65 Ketotransdel 65 cetuximab Erbitux R 65 volociximab 65 Single Dose 65 R Saizen R 65 MT# MEDI 65 TPI ASM8 65 GRN# 65 Telavancin 65 next generation URAT1 65 cancer neuroendocrine tumor 65 nucleotide analogue 65 Panzem NCD 65 bevacizumab Avastin 65 Demonstrates Sustained 65 Paclitaxel Carboplatin 65 Phase #b/#a 65 individualized cellular immunotherapy 65 Shows Statistically Significant 65 Atiprimod 65 evaluating picoplatin 65 Randomized Phase II 64 Ophena 64 Fx #A 64 epothilones 64 small molecule tyrosine 64 VNP#M 64 FOLFOX6 chemotherapy regimen 64 Liprotamase 64 candidate REP# 64 external counterpulsation systems 64 oncolytic vaccine 64 NXL# 64 CCX# B 64 Syncria R 64 pan histone deacetylase 64 Bezielle 64 CD# antibody [001] 64 Pivotal Trials 64 sunitinib malate 64 seliciclib CYC# 64 ZOLINZA 64 refractory gout 64 Naive Patients 64 PTH analogue 64 acadesine 64 DCVax R 64 Antitumor activity 64 Targeted Chemotherapy 64 Sipuleucel T 64 eniluracil 64 Valsartan 64 Octreotide 64 Recombinant Human 64 GLP toxicology studies 64 OncoGel 64 depsipeptide 64 Prodarsan R 64 ATL# [001] 64 Bendamustine 64 XmAb# 64 Matrix Phase 2b 64 BEMA TM Fentanyl 64 PORxin TM 64 neratinib 64 clevidipine 64 PNT# 64 Antibody Drug Conjugate 64 Sphingomab TM 64 metastatic colorectal 64 virus HCV protease inhibitor 64 platform HDL Mimetic 64 non nucleoside HCV 64 G#DT 64 Tesamorelin 64 MAP# 64 refractory chronic lymphocytic 64 immatics 64 methylnaltrexone bromide 64 humanized antibody 64 Oral Spray 64 Aeroquin 64 Pulmonary Arterial Hypertension 64 VitiGam 64 phase IIb 64 metastatic hormone refractory 64 product Fentanyl TAIFUN 64 Fluconazole 64 Intravenous CP 64 immunotherapeutic vaccine 64 novel orally bioavailable 64 ketolide antibiotic 64 GALNS 64 MYDICAR ® 64 Investigational Treatment 64 DEB# 64 oxybutynin ATD TM 64 AzaSite Plus 64 trastuzumab DM1 64 Tipranavir 64 DexaSite 64 BLP# Liposome Vaccine 64 RELOVAIR ™ 64 FDA Approvals 64 MDV# 64 human IgG1 monoclonal 64 MAb 64 phase IIa clinical 64 UPLYSO 64 EDEMA3 64 Palifosfamide 64 Orally administered 64 MTP inhibitor 64 Eniluracil 64 Cardiotoxicity 64 Systemic Delivery 64 Afatinib 64 YONDELIS R 64 Phase 2a clinical 64 BENLYSTA TM 64 Randomized Double Blind 64 platinum chemotherapeutic 64 lipid nanoparticle 64 DOS# 64 SYN# 64 reslizumab 64 oral antiviral 64 plasma kallikrein inhibitor 64 dextromethorphan quinidine 64 Small Molecule 64 Cloretazine VNP#M 64 nucleotide analog 64 Cell Lymphoma 64 CXB# 64 investigational protease inhibitor 64 ROTARIX 64 cannabinor 64 relapsed MM 64 Efficacy Trial 64 drug conjugate 64 BioNumerik 64 Pooled Analysis 64 small molecule chemotherapeutic 64 ongoing Phase 1b 64 ESBA# 64 Empatic ™ 64 Monoclonal 64 nilotinib Tasigna 64 cediranib 64 CRx 64 Phase Ib IIa 64 ZFP Therapeutic 64 EVIZON TM 64 treat chronic sinusitis 64 Empatic TM 64 Cetuximab Erbitux 64 Capesaris 64 OncoVEX GM CSF 64 selective S#P# receptor agonist 64 HuLuc# 64 OMP #R# 64 octreotide implant 64 NP2 Enkephalin 64 Confirmatory Phase 64 hyaluronidase enzyme 64 Tarvacin 64 Universal Flu Vaccine 64 generation nucleoside analog 64 erlotinib Tarceva R 64 Clevudine 64 toenail onychomycosis 64 Cloretazine R 64 tigecycline 64 ProLindac TM 64 ABRAXANE ® 64 Entry Inhibitor 64 BrachySil TM 64 Dabigatran etexilate 64 SYCREST 64 Vascugel 64 THR beta agonist 64 Genasense ® oblimersen 64 LEUKINE 64 lorvotuzumab mertansine 64 BCR ABL inhibitor 64 Zoraxel TM 64 CB2 selective receptor agonist 64 Fibrin Patch 64 Commence Phase 64 mecarbil 64 R sorafenib tablets 64 oral picoplatin 64 TOCOSOL Camptothecin 64 Eltrombopag 64 IV Busulfex 64 TNFerade TM 64 diarrhea predominant irritable 64 Acute Ischemic Stroke 64 NS5b 64 Montelukast 64 R roscovitine CDK cyclin 64 Fidaxomicin 64 apricitabine ATC 64 FDA Accepts 64 anthracycline derivative 64 BiTE ® 64 Late Breaker 64 Clolar ® 64 PDE# 64 AzaSite TM 64 midstage clinical 64 Mycophenolate Mofetil 64 MOVIPREP R 64 farletuzumab 64 RNAi Therapeutics 64 dexpramipexole 64 Anticancer Drug 64 Litx 64 multicenter Phase II 64 Veronate 64 Indomethacin 64 BEMA Granisetron 64 registrational Phase 64 mGluR5 NAM 64 BRAF inhibitor 64 Cethrin R 64 Custirsen 64 perifosine KRX 64 Eluting Stent 64 Initiate Phase II 64 stable nucleic acid 64 RAPAFLO 64 cetuximab Erbitux ® 64 candidate AP# 64 candidate TNFerade biologic 64 Argatroban 64 palifosfamide Zymafos TM 64 MYCAMINE 64 lead Aganocide compound 64 investigational HCV polymerase 64 Troxatyl 64 Omnitarg 64 PROVENGE ® 64 Polymer Microspheres 64 Presents Positive 64 brand ciclesonide HFA 64 Receives Orphan Drug 64 demonstrated antitumor activity